Sign in
CompletedEarly phase 1

Shugan Dingtong Decoction in the Treatment of Fibromyalgia

Key facts

Who runs it
China-Japan Friendship Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Early phase 1
People taking part
72 people enrolled
Started
1 Sept 2022
Ended
18 Oct 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Shugan Dingtong decoction
  • Duloxetine Hydrochloride
Record updated
19 November 2024

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • patients aged 18-70 years old
  • patients who meet the diagnostic criteria of American College of Rheumatology in 2016
  • patients who meet the diagnostic criteria of Syndrome of stagnation of liver qi
  • pain scores between3 and 7 on visual analogue scale
  • patients sign the informed consent forms

Who cannot take part

  • patients are participation in any other clinical trials or receive other drugs for the treatment of fibromyalgia
  • patients with serious primary diseases of respiratory, digestive, urinary, cardiovascular and immune system
  • patients with mental and psychological disorders including cognitive im-pairment, severe depression, somatoform disorders
  • patients with secondary fibromyalgia resulted from osteoarthritis, rheumatoid arthritis, trauma, hypothyroidism, malignant tumor
  • patients who are allergic to the drugs used in this study
  • pregnant and lactating women
  • patients with severe pain resulted from diabetic and postherpetic neuralgia

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Fibromyalgia (FM) is a syndrome characterized by chronic and widespread musculoskeletal pain, fatigue sleep disturbances and cognitive and somatic symptoms. It is commonly conjectured that central sensitization is physiological hallmark of FM. Therefore, centrally acting medications including antidepressants and anticonvulsants are used to treat FM via downregulating dorsal horn sensitization and systemic hyperexcitability.However, those drugs are limited in clinical practice resulting from dose-limiting adverse effects and incomplete drug efficacy.Shugan Dingtong decoction(SGDTD) is a Chinese herbal formula and has been used for treatment of FM in clinical practice many years. However, few research can provide high-quality evidence on the efficacy and safety of SGDTD for the treatment of FM. Therefore, a parallel-group randomized controlled trial was designed to evaluate the efficacy and safety of SGDTD on FM.

The 2 groups in the trial

  • Shugan Dingtong decoctionTreatment being tested

    Patients will accept Shugan Dingtong decoction 150ml (twice, per day) for 12 weeks.

  • duloxetine hydrochlorideExisting treatment, for comparison

    Patients will accept duloxetine hydrochloride 20mg (twice, per day) for 12 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Efficacy and Safety of the Shugan Dingtong Decoction in the Treatment of Fibromyalgia
Publications
Record updated
19 November 2024